Roche is a global healthcare company specializing in pharmaceuticals and diagnostics. Its core products include prescription medications, particularly in oncology, immunology, and neuroscience, as well as diagnostic tools for various diseases. Major business segments are Pharmaceuticals and Diagnostics, with primary revenue sources stemming from drug sales and diagnostic testing services. The company is known for its strong research and development capabilities, contributing to its innovative product pipeline.
Roche's investment profile is characterized by a balanced approach, appealing to investors seeking both growth and dividends. The company offers a stable dividend yield, making it attractive for income-focused investors, while its strong revenue growth indicates potential for capital appreciation. This combination positions Roche as suitable for those looking for a reliable investment with moderate risk.
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-05 02:47 | Vender | Comprar | Strong revenue growth, but mixed momentum signals. |
| 2026-06-03 02:51 | Mantener | Vender | Weak momentum and high risk limit upside potential. |
| 2026-06-01 02:49 | Comprar | Mantener | Solid fundamentals, but mixed momentum signals present uncertainty. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2025-12-10 11:17 | HSBC | Objetivo aumentado | 50 → 57 | 48.66 |
| 2025-10-02 09:07 | HSBC | Rating mejorado | — → 50 | 44.83 |
